Ionis Pharmaceuticals moves forward with FDA review of donidalorsen for HAE

Pallavi Madhiraju- November 4, 2024 0

In a significant development for hereditary angioedema (HAE) patients, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has accepted ... Read More

Ionis Pharmaceuticals to take full ownership of Akcea Therapeutics

pharmanewsdaily- September 1, 2020 0

Ionis Pharmaceuticals is set to take full ownership of Akcea Therapeutics by acquiring the remaining stake of around 24% in the latter for about $500 ... Read More